Navigation Links
Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
Date:10/22/2007

Collaboration with Lentigen Expands Research Applications for RNAi

WALTHAM, Mass., Oct. 22 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has collaborated with Lentigen Corporation to develop a powerful new technology platform that expands applications for RNAi (RNA interference) to critical fields of life sciences research, including neuroscience, immunology and stem cell biology. This advancement, called Thermo Scientific Dharmacon(R) SMARTvector(TM) shRNA Lentiviral Particles, combines Thermo Scientific gene-silencing technologies with Lentigen's expertise in viral-delivery systems. SMARTvector will help researchers overcome common challenges faced when using RNAi, leading to permanent gene silencing in a wide range of cell types.

"With the SMARTvector advancement, we can now effectively deliver stably expressed gene silencing sequences into a broad range of cell types, including those that are difficult to work with, such as primary cells, non-dividing cells, stem cells and neuronal cell lines," said Dr. Ian Jardine, vice president of global research and development for Thermo Fisher Scientific. "Scientists using these cell lines can now harness the power of RNAi in their research, overcoming fundamental limitations in certain existing technologies."

Scientists at Thermo Fisher Scientific have applied innovations in RNAi to develop a novel, dedicated shRNA (short-hairpin RNA) design algorithm that is key to the SMARTvector platform. The algorithm uses criteria unique to shRNA- based silencing for the routine production of highly functional sequences specific to every gene in human, mouse and rat genomes.

"Thermo Fisher Scientific has developed a specialized shRNA design algorithm that greatly enhances the ability to select highly functional gene targeting sequences," added Jardine. "Alternative technologies frequently produce shRNA sequences that are ineffective at silencing the targeted genes, while causing high levels of unintended gene silencing that can lead to flawed experimental results."

By combining shRNA with Lentigen's proprietary viral vector delivery system, the gene silencing sequence is integrated into the host cell genome. This creates permanent gene silencing that cannot be achieved with synthetic siRNAs. Permanent gene silencing is crucial in many types of experiments, including those that examine complex gene networks in drug development and neurobiology.

Dr. Boro Dropulic, founder and chief executive officer of Lentigen, said, "By linking Lentigen's lentiviral technology and production capabilities with the RNAi expertise of Thermo Fisher Scientific, we are giving scientists a new tool that enables a much broader range of experiments involving gene silencing."

Thermo Scientific Dharmacon SMARTvector shRNA Lentiviral Particles can be ordered at http://www.thermo.com/dharmacon .

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With an annual revenue rate of more than $9 billion, we employ 30,000 people and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.

Media Contact Information: Investor Contact Information:

Lori Gorski Ken Apicerno

Phone: 781-622-1242 Phone: 781-622-1111

E-mail: lori.gorski@thermofisher.com E-mail: ken.apicerno@thermofisher.com

Website: http://www.thermofisher.com


'/>"/>
SOURCE Thermo Fisher Scientific Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Study in Cell by Magen BioSciences Co-Founder David E. Fisher Identifies New Roles in Skin Cancer Prevention for Key Tumor Suppressor Protein
2. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
3. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
4. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
5. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
6. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
7. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
8. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
9. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
10. Inspire Announces Presentations at Two European Scientific Conferences
11. HepaLife Announces Scientific Presentation of PBS-1 Cell Line at International Influenza Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/20/2017)... 2017  Prime Therapeutics LLC (Prime) released this statement from ... today,s Institute for Clinical and Economic Review,s (ICER) public ... and value of abuse-deterrent formulations (ADF) of opioids. Prime was ... the meeting. "The ... to the use of abuse-deterrent formulations (ADF) in opioids in ...
(Date:7/14/2017)... DUBLIN , July 14, 2017 Endo International plc ... results on Tuesday, August 8, 2017.  Members of its senior management ... financial markets open at 8:30 a.m. ET. The ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. ... A replay of the ...
(Date:7/13/2017)... July 13, 2017  New York City-based market research firm ... should be aware of.  From new products to new costs, ... in a recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact ... aware of the impact the growing population and, to a ...
Breaking Medicine Technology:
(Date:7/25/2017)... ... July 25, 2017 , ... Dr. ... Arbor University recently co-authored and published an article in the medical science journal ... Plexus Palsy. Both the article and the research that helped produce it, were ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... Facing medical ... father Ezra Clark is taking advantage of a new benefit for employees that is ... means a lot that the company supports me and other employees as new parents. ...
(Date:7/24/2017)... ... 2017 , ... Engineers at the University of Maryland have invented an entirely ... electrical energy that the body uses. , In ordinary batteries the electrical energy, ... out of the battery is generated by moving positive ions from one end to ...
(Date:7/24/2017)... Houston, TX (PRWEB) , ... July 24, 2017 , ... ... $1000 student scholarship will be awarded for the fall semester to a deserving student. ... SignatureCare Emergency Centers Spring 2017 scholarship was awarded to Mariana Castillo who is a ...
(Date:7/24/2017)... , ... July 24, 2017 , ... ... (MCPS) have partnered together for a unique opportunity that helps high school girls succeed ... “Removing Barriers, Creating Opportunities.” Horizon Goodwill will host over 20 high school ...
Breaking Medicine News(10 mins):